Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 20;39(3):30.
doi: 10.1007/s12032-021-01633-4.

Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention

Sharmistha Dey  1 , Abhay Kumar Singh  2 , Abhinay Kumar Singh  3 , Kartik Rawat  3 , Joyita Banerjee  4 , Vertica Agnihotri  3 , Deepak Upadhaya  3
Affiliations
Review

Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention

Sharmistha Dey et al. Med Oncol. .

Abstract

The rapid growth of oral cancer is a significant concern, especially in developing countries due to the advanced lifestyle and 5-year survival despite advanced multimodality of cancer care. The poor modality might be due to the detection of disease in the advanced stage. Early detection and development of novel therapies can improve oral cancer patient survival. The PI3K/AKT/mTOR and RAS-RAF-MEK-ERK are very extensively exploited pathways in oral cancer. These pathways are very critical in the progression of tumorigenesis in oral cancer. This review focuses on the association of Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways in terms of protein expression level, genetic mutation, and therapeutic intervention in oral cancer.

Keywords: Biomarker; Oral cancer; PI3K/AKT/mTOR; Ras/Raf/MEK/ERK; Therapeutic.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gupta N, Gupta R, Acharya AK, Patthi B, Goud V, Reddy S, Garg A, Singla A. Changing trends in oral cancer—a global scenario. Nepal J Epidemiol. 2016;6(4):613–9. https://doi.org/10.3126/nje.v6i4.17255 . - DOI - PubMed - PMC
    1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7(8):606–19. https://doi.org/10.1038/nrg1879 . - DOI - PubMed
    1. Ferreira DM, Neves TJ, Lima LGCA, Alves FA, Begnami MD. Prognostic implications of the phosphatidylinositol 3-kinase/Akt signaling pathway in oral squamous cell carcinoma: overexpression of p-mTOR indicates an adverse prognosis. Appl Cancer Res. 2017;37(1):41–8. https://doi.org/10.1186/s41241-017-0046-4 . - DOI
    1. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res. 2004;10(12 Pt 1):4029–37. https://doi.org/10.1158/1078-0432.CCR-03-0249 . - DOI - PubMed
    1. Monteiro LS, Delgado ML, Ricardo S, Garcez F, do Amaral B, Warnakulasuriya S, Lopes C,. Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma. Oral Surg, Oral Med, Oral Pathol Oral Radiol. 2013;115(5):638–45. https://doi.org/10.1016/j.oooo.2013.01.022 . - DOI

MeSH terms

Substances

LinkOut - more resources